

**PATIENT PACKAGE INSERT IN ACCORDANCE WITH
THE PHARMACISTS' REGULATIONS (PREPARATIONS) – 1986**

This medicine is dispensed with a doctor's prescription only

ENHERTU®

Powder for concentrate for solution for IV infusion

Each vial contains:

Trastuzumab Deruxtecan 100 mg

For inactive ingredients in the medicine - please see section 6 "Further Information".

Read this leaflet carefully in its entirety before using the medicine. This leaflet contains concise information about the medicine. If you have any further questions, ask the doctor or pharmacist.

This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their ailment is similar.

In addition to the leaflet, a Patient Safety Information Card is available for ENHERTU. This card contains important safety information which you must know prior to starting treatment and during the treatment with ENHERTU and follow it. Read the Patient Safety Information Card and the Patient Leaflet prior to starting treatment with the medicinal product. Keep the card for further reading if required.

1. WHAT THE MEDICINE INTENDED FOR?

- **HER2-Positive Metastatic Breast Cancer**

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either:

- in the metastatic setting,

or

- in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.

- **HER2-Low and HER2-Ultralow Metastatic Breast Cancer**

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic:

- Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, that has progressed on one or more endocrine therapies in the metastatic setting
- HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

- **HER2-Mutant Unresectable or Metastatic Non-Small Cell Lung Cancer**

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an approved test, and who have received a prior systemic therapy.

- **HER2-Positive Locally Advanced or Metastatic Gastric Cancer**

ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

- **HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumor**

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

Therapeutic group

Anticancer therapy, monoclonal antibody and chemotherapy conjugate.

2. BEFORE USING THE MEDICINE:

Do not use the medicine if:

- You are sensitive (allergic) to the active ingredient or to any of the other ingredients of this medicine (see section 6).

Special warnings regarding use of ENHERTU

Before treatment with ENHERTU, tell the doctor if:

- You have lung or breathing problems.
- You have signs or symptoms of an infection.
- You have or have had any heart problems.
- You are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Children and adolescents:

There is no information regarding the safety and efficacy of the use of this medicine in children and adolescents.

Drug interactions:

If you are taking, or have recently taken, other medicines, including non-prescription medicines and nutritional supplements, tell the doctor or pharmacist.

Pregnancy, breastfeeding and fertility:

Pregnancy

It is not recommended to take ENHERTU if you are pregnant or might be pregnant, since ENHERTU can harm your fetus.

Inform the doctor immediately if you become pregnant or think you may be pregnant during or before starting treatment with ENHERTU.

If you are a woman of childbearing age, your doctor may do a pregnancy test before you start treatment with ENHERTU.

Breastfeeding

Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose of ENHERTU. It is not known whether ENHERTU passes into your breast milk. Talk to the attending doctor about this.

Contraception

Use effective contraceptives during treatment with ENHERTU.

It is recommended that women of childbearing age will use effective contraceptives during treatment with ENHERTU and for 7 months after the last dose of ENHERTU.

Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.

Fertility

Males treated with ENHERTU who have female partners that are able to become pregnant should avoid pregnancy during treatment with ENHERTU and for 4 months after receiving the last dose.

Use of ENHERTU may cause fertility problems in males, talk to your doctor about this.

Driving and using machines:

It is unlikely that ENHERTU will influence on your ability to drive or operate machines. Be careful if you feel tired, dizzy, or have a headache.

3. HOW SHOULD YOU USE THE MEDICINE?

Always use this medicine according to your doctor's instructions.

Check with the doctor or pharmacist if you are uncertain about the dosage and manner of treatment with this medicine.

The dosage and manner of treatment will be determined by the doctor only.

You will receive ENHERTU into your vein through an intravenous (IV) line by a healthcare provider.

ENHERTU is given 1 time every three weeks (21-day treatment cycle).

Your doctor will decide how many treatments you need.

Your doctor will give you medicines before your infusion to help prevent nausea and vomiting.

Your healthcare provider may slow down or temporarily stop your infusion if you have an infusion related reaction. Treatment may be stopped permanently, if you develop severe infusion reactions.

Do not exceed the recommended dose.

If you have accidentally taken a higher dosage or if a child has accidentally swallowed the medicine, immediately refer to the doctor or to a hospital emergency room and bring the package of the medicine with you.

If you forgot to take the medicine:

If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an alternative appointment. Do not wait until the next planned treatment cycle.

If you stop taking the medicine:

Do not change the dosage or stop treatment with the medicine without consulting the attending doctor.

Continue treatment as recommended by your doctor.

If you have any further questions on the use of this medicine, consult your doctor or pharmacist.

4. SIDE EFFECTS

As with any medicine, use of ENHERTU may cause side effects in some users. Do not be alarmed when reading the list of side effects. You may not suffer from any of them.

ENHERTU can cause serious side effects including:

- **Lung problems that may be severe, life-threatening or that may lead to death.** If you develop lung problems your doctor may treat you with corticosteroid medicines. Tell your doctor right away if you get any of the following signs or symptoms:
 - cough
 - trouble breathing or shortness of breath
 - fever
 - other new or worsening breathing symptoms (e.g., chest tightness, wheezing)
- **Low white blood cell count (neutropenia).** Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your doctor will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your doctor right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.
- **Heart problems that may affect your heart's ability to pump blood.** Your doctor will check your heart function before starting treatment with ENHERTU. Tell your doctor right away if you get any of the following signs or symptoms:
 - new or worsening shortness of breath
 - coughing
 - feeling tired
 - swelling of your ankles or legs
 - irregular heartbeat

- sudden weight gain
- dizziness or feeling light-headed
- loss of consciousness

Your doctor will check you for these side effects during your treatment with ENHERTU. Your doctor may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

The most common side effects of ENHERTU, when used in people with metastatic breast cancer, HER2-mutant non-small cell lung cancer, and other HER2-positive solid tumors include:

- nausea
- low white blood cell counts
- low red blood cell counts
- feeling tired
- vomiting
- hair loss
- increased liver function tests
- low platelet counts
- constipation
- decreased appetite
- diarrhea
- low levels of blood potassium
- pain in muscles or bones

The most common side effects of ENHERTU, when used in people with HER2-positive gastric or gastroesophageal junction adenocarcinoma, include:

- low red blood cell counts
- low white blood cell counts
- low platelet counts

- nausea
- decreased appetite
- increased liver function tests
- feeling tired
- diarrhea
- low levels of blood potassium
- vomiting
- constipation
- fever
- hair loss

If a side effect appears, if any of the side effects worsens, or when you suffer from a side effect not mentioned in the leaflet, consult the doctor.

Reporting of side effects

Side effects can be reported to the Ministry of Health by clicking on the link “Report Side Effects of Drug Treatment” found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects, or by entering the link: <https://sideeffects.health.gov.il>

5. HOW TO STORE ENHERTU?

- Avoid poisoning! This medicine and any other medicine must be kept in a safe place out of the reach and sight of children and/or infants to avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by the doctor!
- Do not use the medicine after the expiry date (exp. date) that appears on the package. The expiry date refers to the last day of that month. In any case of doubt, consult the pharmacist who provided the medicine to you.
- Do not store different medicines in the same package.

- Store refrigerated at 2°C-8°C, in the original carton to protect from light until time of reconstitution. Do not freeze. Do not shake.
- After reconstitution: If not used immediately, store the reconstituted solution in the original vial refrigerated at 2°C to 8°C for up to 24 hours from the time of reconstitution, protected from light.

6. FURTHER INFORMATION

In addition to the active ingredient, the medicine also contains:

Sucrose, L-Histidine hydrochloride monohydrate, L-Histidine, Polysorbate 80

What the medicine looks like and the content of the package?

White to yellowish white powder.

Manufacturer:

Daiichi Sankyo Europe GmbH, Pfaffenhofen, Germany.

License Holder and importer:

AstraZeneca (Israel) Ltd., 1 Atirei Yeda St., Kfar Saba 4464301.

Registration number of the medicine in the National Drug Registry of the Ministry of Health:

167-74-36545-00

Revised in May 2025.

Information intended for healthcare professionals only - Please see on the other side of the page.